1Scherberich JE,Hartinger A. Impact of toll-like receptor sigaling on urinary tract infection[J].International Journal of Antimicrobial Agents,2008,(z1):S9-S14.
2Song J,Abraham SN. TLR-mediated immune response in the urinary tract[J].Current Opinion in Biotechnology,2008,(01):66-73.
5Valiquette L. Urinary tract infections in women. Can J Urol, 2001,8(1) :6 - 12.
6Dwyer PL,O' Reilly M. Recurrent urinary tract infection in the female. Curr (3pin Obstet Gynecol, 2002,14 (5) : 537 - 543.
7Maloney C. Estrogen & recurrent UTI in postmenopausal women. Am J Nurs, 2002,102 (8) : 44 - 52.
8Killgore KM, March KL, Guglie/mo BJ. Risk factors for community acquired ciprofloxacin - resistant Escherichia coli urinary tract infection. Ann Pharmaoother, 2004,38 (7) : 1148.
9Karaca Y, Coplu N, Gozalan A, et al. Co - trimoxazole and quinolone resistance in Escherichia coIi isolated from urinary tract infections over the last 10 years. Int J Antimicrob Agents, 2005,26( 1 ) : 75 - 77.
10Uehling DT, Hopkins WJ, Elkahwaji JE, et al. Phase 2 clinical trial of a vaginalmucosal vaccine for urinary tract infections. J Urol,2003,170(3) :867 - 868.
